Current immunotherapies directed against the inhibitory receptors, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have shown efficacy in various types of cancers that were previously untreatable (3). The gene discussed is CTLA4; the disease is cancer.